Last reviewed · How we verify
FORSTEO
Forsteo (teriparatide) is a recombinant human parathyroid hormone analog that stimulates bone formation by activating PTH1 receptors on osteoblasts.
Forsteo (teriparatide) is a recombinant human parathyroid hormone analog that stimulates bone formation by activating PTH1 receptors on osteoblasts. Used for Osteoporosis in postmenopausal women, Osteoporosis in men at high risk of fracture, Glucocorticoid-induced osteoporosis.
At a glance
| Generic name | FORSTEO |
|---|---|
| Also known as | teriparatide, Teriparatide hormone |
| Sponsor | Shenzhen Salubris Pharmaceuticals Co., Ltd. |
| Drug class | Parathyroid hormone analog |
| Target | PTH1 receptor |
| Modality | Biologic |
| Therapeutic area | Endocrinology / Bone Metabolism |
| Phase | FDA-approved |
Mechanism of action
Teriparatide mimics the action of endogenous parathyroid hormone, which promotes bone anabolism when administered intermittently. It increases osteoblast activity and bone turnover, leading to net gains in bone mineral density. This mechanism differs from antiresorptive agents and makes it particularly effective for severe osteoporosis with high fracture risk.
Approved indications
- Osteoporosis in postmenopausal women
- Osteoporosis in men at high risk of fracture
- Glucocorticoid-induced osteoporosis
Common side effects
- Injection site reactions (erythema, pain)
- Nausea
- Dizziness
- Headache
- Leg cramps
Key clinical trials
- A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants (PHASE1)
- Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo (PHASE1)
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture (NA)
- Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury (PHASE2)
- Effect of Mechanical Loading With PTH on Cortical Bone (PHASE4)
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid (PHASE4)
- Novel Combination Therapy for Osteoporosis in Men (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FORSTEO CI brief — competitive landscape report
- FORSTEO updates RSS · CI watch RSS
- Shenzhen Salubris Pharmaceuticals Co., Ltd. portfolio CI